Prof, Public Health and Medical Research, Charisma University, Grace Bay, Turks and Caicos Islands. Doctor of Health Sciences Candidate, MCPHS University, Boston, Massachusetts, USA
Research Article
Variable vs. Fixed Dosing of Monoclonal Antibodies in Oncology
Author(s): Nikolaos Tzenios*, Mary E. Tazanios and Mohamed Chahine
Oncological patients need the proper doses of medications to facilitate their recovery. The two basic approaches used in dosing Monoclonal Antibodies (mAbs) are fixed-dose combination and variable dosing. In Fixed-Dose Combination Drugs (FDCs), two or more active components are combined in a single formulation at a predetermined dose. Variable dosage, which has long been the industry standard, is the polar opposite of this approach. The body changes over time; the Body Surface Area (BSA) in square meters is often used as a Measure (m2). This study uses a systematic review. Most mAbs used in oncology are predominantly given as cytotoxic anticancer drugs using body-size-based (variable) regimens. Despite the benefits of fixed-dose, variable dosing has become the industry standard, despite being criticized for ineffectiveness. While variable dosing has some advantages, the prevalent view.. View More»
DOI:
10.4172/2572 5130.22.7(10).1000218
